AZN vs MBX: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
AZN is the larger of the two ($272.37B market cap): the incumbent the market prices for continued execution (15.52x forward earnings, beta 0.16). MBX is the smaller challenger ($2.52B), still expected to post a loss next year: more room to run, but more to prove. If the story you believe is AZN's (Oncology franchise and the $80 billion ambition), AZN is the more direct way to own it; if it is MBX's (Canvuparatide in chronic hypoparathyroidism), MBX is.
AZN vs MBX: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | AZN | MBX | What it tells you |
|---|---|---|---|
| Market cap | $272.37B | $2.52B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 15.52 | -11.66 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 0.16 | 0.18 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 37% of range | 53% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 5.27 | 5.33 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how AZN and MBX affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AZN and MBX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AZN and MBX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does AstraZeneca (AZN) do?
AstraZeneca is one of the world's largest biopharmaceutical companies, headquartered in Cambridge, England, with deep Anglo-Swedish roots. It develops and sells prescription medicines across four main areas: oncology (its biggest engine), cardiovascular-renal-metabolism, respiratory and immunology, and rare disease through Alexion, which it acquired in 2021. Flagship products include the cancer drugs Tagrisso, Imfinzi, Calquence, Lynparza (partnered with Merck) and Enhertu (partnered with Daiichi Sankyo), plus the diabetes and heart-failure drug Farxiga and rare-disease therapies like Ultomiris and Soliris. In 2025 the company reported total revenue of about $58.7 billion, up roughly 9%, and it has set a public ambition to grow that to $80 billion by 2030, with about half expected to come from the United States.
What does MBX Biosciences (MBX) do?
MBX Biosciences, Inc. (Nasdaq: MBX) is a clinical-stage biopharmaceutical company focused on discovering and developing novel precision peptide therapies for endocrine and metabolic disorders. Its lead candidate is canvuparatide (MBX 2109), a once-weekly parathyroid hormone peptide prodrug for chronic hypoparathyroidism, which completed its End-of-Phase 2 FDA meeting and dosed the first patient in its registrational Phase 3 oPTimize trial on August 27, 2026. The pipeline also includes an obesity portfolio led by MBX 4291 (a once-monthly candidate in Phase 1), plus two newly nominated development candidates, the amycretin prodrug MBX 5765 and the GLP-1/GIP/glucagon triple-agonist prodrug MBX 6180, and imapextide (MBX 1416) for post-bariatric hypoglycemia in Phase 2. The company was founded around a peptide-engineering platform and went public in September 2024.
AZN vs MBX: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- AZN drivers: Oncology franchise and the $80 billion ambition; Deep late-stage pipeline.
- MBX drivers: Canvuparatide in chronic hypoparathyroidism; Emerging obesity portfolio.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The dominant risk is the patent cliff: from around 2032, Tagrisso, Imfinzi and Calquence are expected to begin losing exclusivity, a headwind analysts have sized at more than $20 billion, so the whole thesis hinges on the pipeline replacing that revenue in time. For MBX, as a pre-revenue clinical-stage biotech, MBX carries binary clinical and regulatory risk: a failed or delayed Phase 3 for canvuparatide, or a negative FDA decision, could sharply reduce the value of the stock.
AZN or MBX: which should you pick?
With growth, valuation and volatility this close (or not yet reported for one side), the drivers above are what separate AZN from MBX. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AZN and MBX guides.
AZN vs MBX: the full fundamentals
AZN. AstraZeneca trades at about 25 times trailing reported earnings but about 15.5 times forward earnings, a gap that reflects heavy amortisation and one-off charges in reported profit and consensus for 2026 EPS near $10.12 rising to about $11.32 in 2027. The forward multiple has edged up from about 14.6 in October as the shares recovered, but it still sits near the low end of where a growth-oriented large-cap pharma usually trades, so the valuation reflects more caution about the 2032 patent cliff than enthusiasm for the $80 billion 2030 goal. Figures are approximate and tied to the asOf date; confirm live numbers before acting.
MBX. MBX has no commercial revenue and runs at a loss, so traditional earnings multiples do not apply. As of November 20, 2026 the shares trade near $50.67 against a 52-week range of roughly $26.00 to $72.64, and the market capitalization of about $2.5 billion is roughly 5.2 times its cash pile, which reflects investor expectations for canvuparatide and the obesity pipeline rather than current fundamentals. Analysts expect a fourth-quarter loss of about $0.93 per share and a 2027 loss of about $4.35 per share; the 11 analysts tracked by Yahoo Finance average a target near $95.
Headline figures (approximate, November 2026): AZN shows revenue (ttm) About $62.4 billion; Q3 2026 revenue about $16.2 billion, up roughly 7% year over year, net income (ttm) About $11.0 billion, a net margin near 18%, with gross margin near 82% and operating margin near 26%, eps Q3 2026 EPS $1.00 vs about $1.15 expected; trailing reported EPS about $7.07, p/e About 25x trailing reported earnings, about 15.5x forward; MBX shows product revenue (ttm) ~$0 (clinical-stage, pre-revenue), q3 2026 net loss ~$62.4 million (EPS -$1.29 vs -$0.84 est.), net income (ttm) ~-$145 million, cash & marketable securities (q3 2026) ~$482 million (runway into 2029).
The bottom line: AZN vs MBX
AZN and MBX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined AZN and MBX exposure against your real portfolio. It is not an investment adviser.
Wondering how AZN or MBX fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about AstraZeneca
Ask Walnut's AI anything about AZN and see how it fits what you own.
FAQ
What is the difference between AZN and MBX?
+
AstraZeneca is one of the world's largest biopharmaceutical companies, headquartered in Cambridge, England, with deep Anglo-Swedish roots. MBX Biosciences, Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is AZN or MBX the better stock?
+
Neither is universally better. AZN is the larger incumbent; MBX is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, AZN or MBX?
+
A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both AZN and MBX?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of AZN vs MBX?
+
AZN: The dominant risk is the patent cliff: from around 2032, Tagrisso, Imfinzi and Calquence are expected to begin losing exclusivity, a headwind analysts have sized at more than $20 billion, so the whole thesis hinges on the pipeline replacing that revenue in time. Generic and biosimilar erosion is already visible, with first generics to Farxiga cleared in 2026. Pipeline risk is constant, since late-stage trial failures such as a disappointing AVANZAR result can erase billions in expected value quickly. China, about a tenth of revenue, carries added uncertainty after the company's former China head was indicted in a compliance case that drew investor lawsuits. Drug pricing policy, US tariffs and currency swings add further volatility, and the balance sheet carries about $34 billion of debt against about $8 billion of cash. As a large-cap pharma the stock can still fall sharply on a single disappointing readout or regulatory decision, as its slide from a 52-week high near $213 to a low near $153 shows. The Q3 2026 EPS shortfall against consensus is a reminder that quarterly earnings can disappoint even as revenue grows. MBX: As a pre-revenue clinical-stage biotech, MBX carries binary clinical and regulatory risk: a failed or delayed Phase 3 for canvuparatide, or a negative FDA decision, could sharply reduce the value of the stock. The company generates no product revenue and posts recurring net losses, so it depends on its cash balance and additional financings that dilute existing shareholders, as the $97.6 million of at-the-market stock sales through September 2026 already did. Competition is real, with Ascendis Pharma's approved Yorvipath already commercial in hypoparathyroidism and AstraZeneca advancing eneboparatide via its Amolyt acquisition, while the obesity field is dominated by well-funded incumbents like Novo Nordisk and Eli Lilly. The valuation near $2.5 billion embeds high expectations for assets that are still years from potential approval, leaving the shares volatile and sensitive to any setback. Losses are widening as the Phase 3 ramps: the second-quarter 2026 loss of $0.78 per share was wider than the $0.59 analysts expected, and the third-quarter loss of $1.29 per share was wider than the $0.84 expected, partly because of $20.8 million of stock compensation tied to the former CEO. The stock is down about 26% over three months, and the fourth-quarter MBX 4291 readout is a near-term event that could move it either way.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell AZN or MBX; figures are approximate and dated (as of November 2026). Verify current data before investing.